Immuno-Oncology Program

The Immuno-Oncology program is designed to help the busy clinician keep on top of the rapidly developing field of immunotherapy as it relates to oncology.  The program address a wide variety of topics including cancer immunobiology, classes of agents, potential predictive biomarkers, clinical activity in the areas of melanoma and non-small cell lung cancer, response determination and the management of immune-related adverse events. 

Learning Objectives
- Describe the components of the normal human immune system and their role in surveillance and anti-tumor activity
- Identify  the mechanisms by which cancer vaccines may induce specific immunity to cancer
- Examine other potential biomarkers of benefit to immune checkpoint blockade
- Identify the immune modulating agents that have been used in the clinic
- Apply RECIST-based response assessments to patients receiving cancer immunotherapy in the clinic
- Describe management strategies for the toxicities associated with immunotherapies

This activity was made available on December 16, 2015 and will be reviewed on an annual basis to determine continued availability.  After successful completion of this activity, American Board of Internal Medicine (ABIM) diplomates are eligible to receive 8 points in medical knowledge.  Participants can also earn a maximum of 8.0 AMA PRA Category 1 Credit(s)™ 

ACGME Competencies addressed: Medical Knowledge

IMPORTANT NOTE: The Immuno-Oncology Program expires on December 16, 2018. Users must complete all necessary course components by this date to be eligible to claim MOC and CME credit.

This course is accessible through mobile devices as well as personal computers